ImmunityBio wins UAE approval for ANKTIVA cancer therapies
I'm LongbridgeAI, I can summarize articles.ImmunityBio (IBRX) received UAE marketing authorization for ANKTIVA in two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This expands approvals to 34 countries, making the UAE the first to approve ANKTIVA with BCG for the full spectrum of bladder cancer. The approval is supported by trial data showing durable responses. Analyst ratings are mixed, with a Buy rating at $15.00 target and an AI analyst rating of Neutral due to weak financials despite strategic progress.
ImmunityBio ( (IBRX) ) has shared an announcement.
On July 29, 2026, ImmunityBio announced that the Emirates Drug Establishment of the United Arab Emirates granted marketing authorization for ANKTIVA in two indications, expanding the drug’s approvals to 34 countries and marking the broadest authorization to date. The UAE became the first jurisdiction worldwide to approve ANKTIVA with BCG across the full spectrum of BCG-unresponsive non-muscle invasive bladder cancer, covering carcinoma in situ with or without papillary tumors as well as papillary disease alone.
The regulator also authorized ANKTIVA in combination with immune checkpoint inhibitors for adult patients with metastatic non-small cell lung cancer whose disease has progressed after standard-of-care therapies, including checkpoint inhibitors and chemotherapy. These decisions, supported by QUILT-3.032 and QUILT-3.055 trial data showing durable responses and survival benefits, strengthen ImmunityBio’s position in addressing major unmet needs in bladder and lung cancers and enhance its commercial opportunities in the Middle East oncology market.
The most recent analyst rating on (IBRX) stock is a Buy
with a $15.00 price target.
To see the full list of analyst forecasts on ImmunityBio stock,
see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
The score is held back primarily by weak financial performance (large losses, heavy cash burn, and negative equity) despite improving revenue and reduced debt. Technicals are supportive with the stock trading above major moving averages, but momentum is nearing overbought. Valuation remains challenged due to negative earnings, while corporate events are net mixed with strategic progress offset by regulatory risk.
To see Spark’s full report on IBRX stock,
click here.
More about ImmunityBio
ImmunityBio, Inc. (NASDAQ: IBRX) is a vertically integrated commercial-stage biotechnology company focused on developing and commercializing immunotherapies for cancer. Its lead product, ANKTIVA (nogapendekin alfa inbakicept), targets activation of natural killer cells and T cells, with a growing global regulatory footprint now spanning 34 countries across multiple oncology indications.
Average Trading Volume: 12,729,497
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.3B